On September 12, Nimbus Therapeutics announced the completion of a $125 million private placement financing. Participating in this round of financing includes two new investors Bain Capital Life Sciences and SV Health Investors, other old investors such as Bill Gates, Pfizer Ventures, RA Capital Management, Atlas Venture and others also participated.
This round of financing will be used for the ongoing Phase IIb clinical trial of NDI-034858, an oral allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis , initiated a Phase III trial in psoriasis, and a Phase IIb clinical trial of NDI-034858 in other autoimmune indications, including inflammatory bowel disease and lupus. In addition, this round of financing will support the ongoing Phase I/II clinical trial of the hematopoietic stem cell kinase 1 (HPK1) inhibitor NDI-101150 in solid tumors, targeting Casitas b-lineage lymphoma b (Cbl-b) and Werner syndrome Helicase (WRN) preclinical development program, and ongoing discovery of a range of targets.
Massachusetts-based Nimbus is a clinical-stage, structure-based drug discovery company that combines cutting-edge computational techniques with a range of machine-learning-based predictive modeling approaches to target well-validated but difficult-to-follow human diseases. The target of development, the development of new small molecule drugs.
Nimbus applies cutting-edge computational chemistry combined with other techniques to more efficiently use high-resolution protein structural data for drug targets and modulate their functional activity. Atomic-resolution structural data of the target is generated through a range of techniques including X-ray crystallography and cryo-electron microscopy (cryo-EM). Leverage the founding partners’ Schrödinger’s technology and expertise to perform physics-based analysis of target activity and allosteric sites and design small molecule modulators with desired binding modes, functional activity, and selectivity. Nimbus designs, discovers and develops a variety of clinical and preclinical programs focusing on inflammatory and autoimmune diseases, cancer and metabolic diseases.
Nimbus is backed by world-class life science investors, and the company has received more than $400 million in private investment since 2011.
Dr. Nikola Trbovic, Partner at SV Health Investors, said: “We are honored to lead this financing round to advance Nimbus’ clinical and preclinical drug candidates. Nimbus is in the process of discovering and developing differentiated small molecule therapeutics to address a large number of unmet needs. has an excellent track record of success in addressing the medical needs of the company, and we are delighted to support their current program.”
Jeb Keiper, CEO of Nimbus, said: “The strong investor support for this financing is a testament to the commitment and differentiation of Nimbus’ current portfolio of clinical and preclinical programs, as well as the success of our highly efficient drug discovery engine. Welcome SV Health Investors and Bain Capital Life Sciences joins Nimbus’ investors at this exciting time and looks forward to sharing key data on the drugs we are developing in the near term.”